Such a mechanism may provide an additional layer of regulatory control over PRMT5-dependent signaling in endocrine tumor contexts, linking upstream kinase activity to chromatin-associated transcriptional programs. This evidence concerns the gene PRMT5 and malignant endocrine neoplasm.